Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

Ítems similars

• Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
  per: Broucek, Joseph, et al.
  Publicat: (2014)
• Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
  per: Zloza, Andrew, et al.
  Publicat: (2013)
• NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
  per: Kohlhapp, Frederick J, et al.
  Publicat: (2015)
• Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy
  per: Kohlhapp, Frederick, et al.
  Publicat: (2015)
• Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells
  per: Kim, Dae Won, et al.
  Publicat: (2014)